Actively Recruiting
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
Led by University of California, Davis · Updated on 2025-01-06
300
Participants Needed
1
Research Sites
378 weeks
Total Duration
On this page
Sponsors
U
University of California, Davis
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.
CONDITIONS
Official Title
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have one of these confirmed cancers: esophageal, gastroesophageal junction, gastric, small bowel, colorectal, appendiceal, biliary (including gallbladder and cholangiocarcinoma), hepatocellular carcinoma, pancreatic, or ampullary cancer
- Be 18 years or older at the time of consent
- Currently receiving systemic therapy and eligible to continue with no more than a 30-day planned break for local ablative therapy
- Have received at least one line of systemic therapy for metastatic disease with at least 3 months of clinical benefit on the most recent therapy before new metastatic lesions appeared
- Have no more than five progressing or new metastatic lesions
- All progressing or new metastatic lesions must be safely treatable with locally ablative therapies as determined by the treating specialists
- Provide signed and dated informed consent
- Willing to comply with all study procedures and remain available for the study duration
You will not qualify if you...
- Have medical conditions that prevent use of locally ablative therapies
- History of treatment-related toxicities that limit or prevent locally ablative therapies
- Presence of progressing brain (intracranial) lesions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California, Davis
Sacramento, California, United States, 95817
Actively Recruiting
Research Team
S
Selina Laqui
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here